期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 22, 期 24, 页码 -出版社
MDPI
DOI: 10.3390/ijms222413317
关键词
latent tuberculosis infection; dormant Mycobacterium tuberculosis; LTBI treatment; anti-TB drugs
资金
- Russian Science Foundation [21-15-00042, rscf.ru/project/21-15-00042]
- Russian Science Foundation [21-15-00042] Funding Source: Russian Science Foundation
Current guidelines for managing latent tuberculosis infection (LTBI) only include three older drugs, which have little impact on eliminating latent TB. New specific therapeutics are urgently needed to address this challenge.
Latent tuberculosis infection (LTBI) represents a major challenge to curing TB disease. Current guidelines for LTBI management include only three older drugs and their combinations-isoniazid and rifamycins (rifampicin and rifapentine). These available control strategies have little impact on latent TB elimination, and new specific therapeutics are urgently needed. In the present mini-review, we highlight some of the alternatives that may potentially be included in LTBI treatment recommendations and a list of early-stage prospective small molecules that act on drug targets specific for Mycobacterium tuberculosis latency.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据